Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E18.48 EPS (ttm)1.59 Insider Own0.10% Shs Outstand6.34B Perf Week1.94%
Market Cap186.29B Forward P/E13.10 EPS next Y2.24 Insider Trans10.11% Shs Float6.34B Perf Month0.41%
Income10.37B PEG5.96 EPS next Q0.55 Inst Own72.00% Short Float1.15% Perf Quarter0.03%
Sales50.33B P/S3.70 EPS this Y37.50% Inst Trans0.30% Short Ratio3.13 Perf Half Y-6.88%
Book/sh12.03 P/B2.44 EPS next Y-0.13% ROA17.20% Target Price34.02 Perf Year7.70%
Cash/sh5.37 P/C5.47 EPS next 5Y3.10% ROE38.70% 52W Range26.89 - 32.38 Perf YTD-1.57%
Dividend1.04 P/FCF17.44 EPS past 5Y6.80% ROI10.50% 52W High-9.27% Beta0.68
Dividend %3.54% Quick Ratio2.40 Sales past 5Y1.30% Gross Margin81.30% 52W Low9.25% ATR0.36
Employees77700 Current Ratio2.70 Sales Q/Q-1.50% Oper. Margin33.40% RSI (14)57.31 Volatility0.82% 1.26%
OptionableYes Debt/Eq0.49 EPS Q/Q-10.00% Profit Margin59.30% Rel Volume0.84 Prev Close29.49
ShortableYes LT Debt/Eq0.42 EarningsJul 29 BMO Payout22.50% Avg Volume23.17M Price29.38
Recom2.30 SMA202.49% SMA500.09% SMA200-2.31% Volume19,547,780 Change-0.37%
02-Jul-13Downgrade Standpoint Research Hold → Sell $24
15-Apr-13Reiterated Barclays Equal Weight $25 → $32
30-Jan-13Reiterated UBS Buy $29 → $31
30-Jan-13Reiterated Argus Buy $28 → $32
22-Jan-13Reiterated Barclays Equal Weight $24 → $25
27-Nov-12Downgrade MKM Partners Buy → Neutral $29 → $25
05-Oct-12Reiterated MKM Partners Buy $27 → $29
01-Nov-11Downgrade Standpoint Research Buy → Hold
07-Oct-11Initiated MKM Partners Buy $20.50
14-Sep-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
10-Aug-11Upgrade Argus Hold → Buy $21
05-Aug-11Upgrade Standpoint Research Hold → Buy $21
14-Mar-11Downgrade Standpoint Research Buy → Hold
03-Nov-10Downgrade Argus Buy → Hold
21-May-10Initiated Jefferies Buy $17.80
16-Dec-09Initiated UBS Buy
27-Apr-09Initiated Standpoint Research Buy $20
12-Feb-09Upgrade Leerink Swann Mkt Perform → Outperform
09-Feb-09Upgrade UBS Neutral → Buy
02-Feb-09Upgrade Credit Suisse Neutral → Outperform
28-Aug-14 06:42PM  Amgen edges up on trial results Investor's Business Daily
05:03PM  Fed Chair Yellen's assets up 8% during 2013 at USA TODAY
03:56PM  AstraZeneca Pops on Possibility of Another Pfizer Bid at The Wall Street Journal
01:15PM  Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease Business Wire
09:40AM  [$$] Pfizer Vaccine Candidate Gets Fast Track at The Wall Street Journal
09:13AM  [$$] Pfizer Vaccine Candidate Gets Fast Track at The Wall Street Journal
08:45AM  [$$] Pfizer Vaccine Candidate Gets Fast Track at The Wall Street Journal
08:00AM  Pfizers Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation Business Wire
06:34AM  French leader banks on free market to save economy AP
27-Aug-14 06:15PM  Your first trade for Thursday at CNBC
06:00PM  Pfizer and Merck Collaborate to Develop Lung Cancer Therapy Zacks
05:58PM  [video] Fast Money Final Trade: PFE, GDX, DOW, WFT at CNBC
04:11PM  Stocks little moved as S&P 500 ends above 2,000 again at CNBC
04:04PM  Stocks little moved as S&P 500 ends above 2,000 again at CNBC
03:15PM  US stocks fluctuate; S&P 500 near milestone at CNBC
02:03PM  US stocks fluctuate; S&P 500 near milestone at CNBC
01:11PM  [video] Options Insight: Unusual Activities on The Dow at Bloomberg
12:48PM  US stocks fluctuate; S&P 500 near milestone at CNBC
11:34AM  [video] Facebook and Movado Downgraded, Deutsche Initiates Drugmakers at TheStreet
11:25AM  Deutsche Bank Says Pfizer Has A Strong Financial Position And Attractive Pipeline Benzinga
11:11AM  US stocks fluctuate; S&P 500 near milestone at CNBC
11:00AM  [video] Merck & Pfizer team up at CNBC
10:39AM  US stocks fluctuate; S&P 500 near milestone at CNBC
10:26AM  Stocks edge mostly lower; S&P 500 dips below 2,000 at CNBC
09:59AM  [video] MassChallenge CEO Says Future is Bright for U.S. Entrepreneurship at TheStreet
09:09AM  Will This New Rating Help Pfizer (PFE) Stock Today? at TheStreet
26-Aug-14 04:10PM  Stocks rise; S&P 500 scores first finish above 2,000 at CNBC
12:46PM  Midday movers: Ann, Best Buy Co., Exxon & more at CNBC
12:07PM  Merck, Pfizer Combining Drugs In Lung Cancer Study at Investor's Business Daily
09:07AM  Pfizer to test Xalkori lung cancer drug with Merck immunotherapy Reuters
09:02AM  Stock futures hold mild gains amid economic reports at CNBC
08:42AM  [$$] Pfizer, Merck Team Up on Cancer Study at The Wall Street Journal
08:00AM  Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen Business Wire
03:16AM  Pfizer/AstraZeneca: Ready for round 2? at CNBC
25-Aug-14 03:14PM  [video] Whats Behind the Surge in Pharmaceutical Deals? at Bloomberg
02:07PM  Business events scheduled for Tuesday AP
01:24PM  Why Jim Cramer Thinks Merck (MRK), Pfizer (PFE), GlaxoSmithKline (GSK) Bids Are Coming After InterMune (ITMN) Deal at TheStreet
12:10PM  [video] Jim Cramer Says Roche's "Bolt-On" Acquisition Means Big Pharma is Thinking Big at TheStreet
09:06AM  [video] Roche's $8.3 billion deal for InterMune at CNBC
09:00AM  Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection PR Newswire
24-Aug-14 09:26PM  Roche's InterMune Acquisition Underscores How It And Pfizer Are On Different M&A Paths at Forbes
22-Aug-14 04:55PM  Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod Zacks
03:46PM  ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection PR Newswire
02:24PM  Glaxo, Pfizers ViiV Wins Approval for HIV Combo Drug at Bloomberg
09:00AM  Heart Doctor Pay Drops To $558K As Interventions Scrutinized at Forbes
21-Aug-14 03:10PM  FDA clears Eliquis for new use against blood clots AP
03:00PM  Contract Researcher Parexel Sees Growth In Biotech at Investor's Business Daily
02:48PM  Where Are You Looking For Yield Today? at Forbes
02:44PM  ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms 24/7 Wall St.
01:56PM  FDA OKs use of Eliquis to treat leg, lung clots Reuters
01:31PM  U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy Business Wire
12:03PM  Video: Illumina Partners With Big Pharma Firms at Investor's Business Daily
12:03PM  Illumina Forms Partnerships With Big Pharma Firms at Investor's Business Daily
09:35AM  Why AstraZeneca (AZN) Stock Is Higher Today at TheStreet
09:19AM  Pfizer back for AstraZeneca? Year-end move seen most likely Reuters
08:55AM  Lilly psoriasis drug fares well in late-stage test AP
08:00AM  Palbociclib Expanded Access Program Now Open To Eligible U.S. Patients With HR+, HER2- Advanced Breast Cancer Business Wire
20-Aug-14 07:00PM  AstraZeneca Is Tougher Target for Possible New Pfizer Bid Bloomberg
07:00PM  AstraZeneca Is Tougher Target for Possible New Pfizer Bid at Bloomberg
03:27PM  Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy Zacks
02:10PM  Baxter International Expands Dialyzers Facility in Alabama Zacks
09:45AM  Flatley's Law: How One Company Is Creating Medicine's Genetic Revolution at Forbes
09:45AM  Flatley's Law: How One Company Created Medicine's Genetic Revolution at Forbes
08:00AM  Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014 Business Wire
19-Aug-14 06:27PM  This stock may be hazardous to your financial health Talking Numbers
03:20PM  Pfizer Submits Palbociclib Marketing Application to the FDA Zacks
08:37AM  The Negative Impact Of Pfizer's Mergers And Budget Cuts On Cancer R&D at Forbes
07:45AM  DoJ closes AstraZeneca probe without bringing charges at Financial Times
18-Aug-14 08:13AM  Washington Post Off Base In Critiquing Pharma Efforts In Ebola at Forbes
08:00AM  Premier Biotechnology & Anti-CTLA4 Accesswire
08:00AM  Pfizer Announces Submission of Palbociclib New Drug Application to the FDA Business Wire
01:36AM  Japan's Eisai Steps Up Push in Cancer Drugs at The Wall Street Journal
15-Aug-14 05:50PM  Pfizer is Liable for Harm Caused by a Generic Version of its Drug: Court at The Wall Street Journal
05:19PM  Pfizer is Liable for Harm Caused by a Generic Version of its Drug: Court at The Wall Street Journal
04:03PM  Why tax inversions are bad for shareholders at MarketWatch
01:04PM  PFIZER INC Financials EDGAR Online Financials
10:32AM  Do We Really Trust Corporations To Investigate Their Own Profitable Impropriety? at Forbes
10:13AM  Digital Transformation Moves Pharma 'Beyond the Pill' at Forbes
10:13AM  Digital Transformation Moves Pharma "Beyond the Pill" at Forbes
14-Aug-14 05:01PM  Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine Business Wire
04:23PM  Stocks close up in light volume on easing geopolitics at CNBC
04:10PM  Pfizer's Prevnar 13 Backed by U.S. Panel for Expanded Use Zacks
02:57PM  [video] Pfizer and Merck Receive Key Regulatory Approvals at TheStreet
02:16PM  Daniel Loeb's Third Point Reveals AstraZeneca Stake at The Wall Street Journal
01:51PM  [video] Howard Hughes, Pfizer Will Head Higher Says Becker Fund Manager at TheStreet
01:05PM  Cohen, Point72 must face SAC insider trading lawsuit-judge Reuters
11:43AM  SAC Loses Bid to Dismiss Investor Inside Trading Suit at Bloomberg
10:46AM  U.S. judge lets investors pursue SAC insider trading lawsuit Reuters
09:34AM  [video] Companies that innovate get bids: Cramer at CNBC
09:05AM  7 things you absolutely must know about corporate taxes at CNNMoney.com
08:25AM  Why Pfizer (PFE) Stock Is Up Today at TheStreet
06:01AM  Bob Doll doubles down on 2014 picks, adds three more Yahoo Finance
12:01AM  U.S. Panel Says Seniors Should Get Pfizers Prevnar 13 at Bloomberg
13-Aug-14 05:42PM  Advisory Committee on Immunization Practices Votes to Recommend Pfizers Prevnar 13® Vaccine in Adults Aged 65 Years and Older Business Wire
04:01PM  Bob Doll doubles down on 2014 picks, adds three more Yahoo Finance
10:00AM  Despite Obamacare Rules, Employer Cost Trend Slows In 2015 at Forbes
09:40AM  [video] Faber Report: New wave of tax inversions? at CNBC
08:10AM  Athersys Loss In Line with Expectations, Revenues Down Y/Y Zacks
12-Aug-14 05:01PM  Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica® Studies Conducted in China Business Wire
04:21PM  Williams Among Many Who Cracked Jokes While Fighting Depression Bloomberg
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company's Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The company's Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company also offers Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It serves wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. It has strategic alliance with CliniWorks (Israel) Ltd. to develop population health management platform with advanced analytics and patient care capabilities. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OLSON LAURIE JExecutive Vice PresidentJun 12Option Exercise26.2036,275950,40593,010Jun 13 12:29 PM
OLSON LAURIE JExecutive Vice PresidentJun 12Sale29.5336,2751,071,27856,735Jun 13 12:29 PM
YOUNG JOHN DGroup PresidentMar 17Sale31.389,000282,42099,647Mar 18 09:33 AM
PFIZER INC10% OwnerMar 12Buy11.00272,7272,999,9971,235,330Mar 14 03:27 PM
SUSMAN SALLYExecutive Vice PresidentMar 04Sale32.5967,5852,202,872173,637Mar 05 05:36 PM
Dolsten MikaelPresident R&DMar 04Sale32.5835,7891,165,929344,571Mar 05 05:36 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerMar 04Sale32.555,082165,419171,756Mar 05 05:37 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerMar 03Option Exercise26.2075,5001,978,100274,699Mar 05 05:37 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerMar 03Sale32.0297,8613,133,674176,838Mar 05 05:37 PM
READ IAN CChairman & CEOFeb 26Option Exercise12.70324,9324,126,6361,410,536Feb 28 04:52 PM
SUSMAN SALLYExecutive Vice PresidentFeb 26Option Exercise12.70130,8751,662,113312,499Feb 28 04:52 PM
YOUNG JOHN DGroup PresidentFeb 26Option Exercise12.7057,586731,342116,884Feb 28 04:52 PM
BOURLA ALBERTGroup PresidentFeb 26Option Exercise12.7021,482272,82192,447Feb 28 04:52 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 26Option Exercise12.7056,411716,420228,878Feb 28 04:52 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 26Option Exercise12.70324,9324,126,636615,673Feb 28 04:52 PM
HILL CHARLES HExecutive Vice PresidentFeb 26Option Exercise12.7034,731441,084104,046Feb 28 04:52 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 26Option Exercise12.7034,568439,014120,562Feb 28 04:52 PM
JOHNSON RADY AExecutive Vice PresidentFeb 26Option Exercise12.7029,695377,12740,480Feb 28 04:52 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 26Option Exercise12.7029,695377,12783,716Feb 28 04:52 PM
OLSON LAURIE JExecutive Vice PresidentFeb 26Option Exercise12.7031,772403,50468,167Feb 28 04:52 PM
PFIZER INC10% OwnerFeb 04Buy8.00227,2611,818,0881,794,803Feb 06 03:53 PM
DAMELIO FRANK AExecutive Vice PresidentJan 13Sale30.82131,8104,062,225356,451Jan 14 07:13 PM
DAMELIO FRANK AExecutive Vice PresidentJan 13Sale30.8628,190869,817328,261Jan 14 07:13 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 14Option Exercise26.2092,0002,410,400152,447Nov 18 03:31 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 14Sale32.1092,0002,953,06360,447Nov 18 03:31 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerNov 01Sale31.2010,000311,985174,841Nov 04 03:59 PM
READ IAN CChairman & CEOOct 28Option Exercise26.20338,0008,855,6001,412,267Oct 29 05:44 PM
READ IAN CChairman & CEOOct 28Sale30.57338,00010,331,3151,074,267Oct 29 05:44 PM
LANKLER DOUGLAS MExecutive Vice PresidentSep 16Option Exercise26.0660,9001,587,198150,617Sep 18 04:27 PM
LANKLER DOUGLAS MExecutive Vice PresidentSep 16Sale28.7060,9001,748,02589,717Sep 18 04:27 PM
Lewis-Hall Freda CExecutive Vice PresidentSep 16Sale28.7038,4611,103,831118,383Sep 18 04:20 PM